Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines.
A major component in green tea, epigallocatechin-3-gallate (EGCG), is reported to interfere with different steps of a number of inflammatory pathways. After oral administration, EGCG is retained in the gastrointestinal tract, where it is thought to exert preventive functions against inflammatory bowel disease and colon cancer. In this study, the human colon adenocarcinoma cell lines HT29 and T84 were used to investigate the effect of EGCG on intestinal inflammation. HT29 and T84 cells were stimulated with tumor necrosis factor (TNF)-alpha to induce the inflammatory condition and to trigger the inflammatory cascade in vitro and treated with EGCG to study its effect on inflammatory processes. The secretion of the chemokines interleukin (IL)-8, macrophage inflammatory protein (MIP)-3alpha, and prostaglandin E2 (PGE2) was determined by enzyme-linked immunosorbent assay. The gene expression level was measured by quantitative real-time polymerase chain reaction. Treatment of TNF-alpha-stimulated HT29 cells with EGCG dose-dependently inhibited the synthesis of IL-8, MIP-3alpha, and PGE2. Treatment with EGCG also inhibited the production of IL-8 and MIP-3alpha in TNF-alpha-stimulated T84 cells. Gene expression analysis in both HT29 and T84 cells revealed that EGCG down-regulates genes involved in inflammatory pathways. This study shows that EGCG acts broadly on the production of chemokines and PGE2 in the chemokine and eicosanoid pathways of colon epithelial cells. Therefore, EGCG might prove useful for the prevention and/or attenuation of colonic disorders.
Porath
Debora
D
DSM Nutritional Products Ltd., Building 205/209, P.O. Box 3255, Wurmisweg 576, CH-4303 Kaiseraugst, Switzerland.
Riegger
Christoph
C
Drewe
Juergen
J
Schwager
Joseph
J
D000975:Antioxidants / Q000633:toxicity*; D002392:Catechin / Q000031:analogs & derivatives* / Q000633:toxicity; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D018925:Chemokines / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003106:Colon / Q000166:cytology*; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology; D015232:Dinoprostone / Q000032:analysis / Q000037:antagonists & inhibitors; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000187:drug effects*; D019073:HT29 Cells; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis / Q000037:antagonists & inhibitors; D007700:Kinetics; D019402:Macrophage Inflammatory Proteins / Q000032:analysis / Q000037:antagonists & inhibitors; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
D000975:Antioxidants; D018925:Chemokines; D016209:Interleukin-8; D019402:Macrophage Inflammatory Proteins; D014409:Tumor Necrosis Factor-alpha; D002392:Catechin; C045651:epigallocatechin gallate; D015232:Dinoprostone